World Maternal Antifibrinolytic Trial

All legally adult women with postpartum haemorrhage following vaginal or caesarean
section delivery who have a clinical diagnosis of postpartum haemorrhage. The clinical
diagnosis of PPH may be based on any of the following:

- Blood loss after vaginal delivery > 500 mL OR

- > 1,000 mL after caesarean section OR blood loss sufficient to compromise the
haemodynamic status of the woman The fundamental eligibility criterion is the
responsible clinician's 'uncertainty' as to whether or not to use an
antifibrinolytic agent in a particular woman with postpartum haemorrhage.

- Women for whom the responsible doctor considers there is a clear indication for
antifibrinolytic therapy should not be randomised.

- Women for whom there is considered to be a clear contraindication to
antifibrinolytic therapy should not be randomised.

Where the responsible clinician is substantially uncertain as to whether or not to use an
antifibrinolytic, all these women are eligible for randomisation and should be considered
for the trial.

There are no other pre-specified exclusion criteria.